S&P 500   3,266.78 (+0.62%)
DOW   26,914.43 (+0.37%)
QQQ   268.11 (+1.02%)
AAPL   110.12 (+1.76%)
MSFT   205.95 (+1.36%)
FB   250.54 (+0.40%)
GOOGL   1,423.12 (+0.02%)
AMZN   3,047.34 (+0.91%)
TSLA   404.72 (+4.37%)
NVDA   505.42 (+2.33%)
BABA   267.14 (-0.96%)
CGC   13.98 (-2.03%)
GE   6.03 (-0.50%)
MU   48.17 (-2.63%)
AMD   76.63 (+1.07%)
T   27.78 (-0.93%)
F   6.52 (-2.10%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.72 (+0.77%)
DIS   122.17 (-0.26%)
BAC   23.22 (-0.51%)
BA   150.54 (+3.07%)
S&P 500   3,266.78 (+0.62%)
DOW   26,914.43 (+0.37%)
QQQ   268.11 (+1.02%)
AAPL   110.12 (+1.76%)
MSFT   205.95 (+1.36%)
FB   250.54 (+0.40%)
GOOGL   1,423.12 (+0.02%)
AMZN   3,047.34 (+0.91%)
TSLA   404.72 (+4.37%)
NVDA   505.42 (+2.33%)
BABA   267.14 (-0.96%)
CGC   13.98 (-2.03%)
GE   6.03 (-0.50%)
MU   48.17 (-2.63%)
AMD   76.63 (+1.07%)
T   27.78 (-0.93%)
F   6.52 (-2.10%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.72 (+0.77%)
DIS   122.17 (-0.26%)
BAC   23.22 (-0.51%)
BA   150.54 (+3.07%)
S&P 500   3,266.78 (+0.62%)
DOW   26,914.43 (+0.37%)
QQQ   268.11 (+1.02%)
AAPL   110.12 (+1.76%)
MSFT   205.95 (+1.36%)
FB   250.54 (+0.40%)
GOOGL   1,423.12 (+0.02%)
AMZN   3,047.34 (+0.91%)
TSLA   404.72 (+4.37%)
NVDA   505.42 (+2.33%)
BABA   267.14 (-0.96%)
CGC   13.98 (-2.03%)
GE   6.03 (-0.50%)
MU   48.17 (-2.63%)
AMD   76.63 (+1.07%)
T   27.78 (-0.93%)
F   6.52 (-2.10%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.72 (+0.77%)
DIS   122.17 (-0.26%)
BAC   23.22 (-0.51%)
BA   150.54 (+3.07%)
S&P 500   3,266.78 (+0.62%)
DOW   26,914.43 (+0.37%)
QQQ   268.11 (+1.02%)
AAPL   110.12 (+1.76%)
MSFT   205.95 (+1.36%)
FB   250.54 (+0.40%)
GOOGL   1,423.12 (+0.02%)
AMZN   3,047.34 (+0.91%)
TSLA   404.72 (+4.37%)
NVDA   505.42 (+2.33%)
BABA   267.14 (-0.96%)
CGC   13.98 (-2.03%)
GE   6.03 (-0.50%)
MU   48.17 (-2.63%)
AMD   76.63 (+1.07%)
T   27.78 (-0.93%)
F   6.52 (-2.10%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.72 (+0.77%)
DIS   122.17 (-0.26%)
BAC   23.22 (-0.51%)
BA   150.54 (+3.07%)
Log in
NASDAQ:PRFX

PainReform Stock Forecast, Price & News

$5.12
-0.16 (-3.03 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.12
Now: $5.12▼
$5.45
50-Day Range N/A
52-Week Range
$5.12
Now: $5.12▼
$7.85
Volume11,353 shs
Average Volume39,878 shs
Market Capitalization$45.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.00 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRFX
Previous Symbol
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares8,910,000
Market Cap$45.62 million
Next Earnings DateN/A
OptionableNot Optionable
$5.12
-0.16 (-3.03 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRFX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PainReform (NASDAQ:PRFX) Frequently Asked Questions

Who are some of PainReform's key competitors?

Some companies that are related to PainReform include Avenue Therapeutics (ATXI), Kindred Biosciences (KIN), NeuBase Therapeutics (NBSE), LifeVantage (LFVN), Axovant Gene Therapies (AXGT), Unity Biotechnology (UBX), Milestone Pharmaceuticals (MIST), Alpine Immune Sciences (ALPN), Mustang Bio (MBIO), BIOFRONTERA AG/ADR (BFRA), ADMA Biologics (ADMA), Evofem Biosciences (EVFM), Theratechnologies (THTX), Theratechnologies (THERF) and TAIWAN LIPOSOME/S (TLC).
View all competitors.

Who are PainReform's key executives?

PainReform's management team includes the following people:
  • Dr. Ehud Geller Ph.D., Exec. Chairman & Acting CFO
  • Prof. Eli Hazum Ph.D., Acting CEO, CTO & Director
  • Dr. David E. Weinstein, Pres & Chief Medical Officer (Age 62)
  • Dr. Sigal Aviel, Chief Operating Officer (Age 56)
  • Dr. Stephen A. Cooper D.M.D Ph.D., Exec. VP of Devel.

When did PainReform IPO?

(PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO.

What is PainReform's stock symbol?

PainReform trades on the NASDAQ under the ticker symbol "PRFX."

When does PainReform's quiet period expire?

PainReform's quiet period expires on Monday, October 12th. PainReform had issued 2,500,000 shares in its public offering on September 1st. The total size of the offering was $20,000,000 based on an initial share price of $8.00. During PainReform's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of PainReform?

Shares of PRFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PainReform's stock price today?

One share of PRFX stock can currently be purchased for approximately $5.12.

How big of a company is PainReform?

PainReform has a market capitalization of $45.62 million.

This page was last updated on 9/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.